+61 8 8159 6233

We are excited to now offer a robust and fully validated multiplex Cannabinoid assay in human plasma and are currently running sample analysis of our clients’ medical cannabis studies.

Tom Midgley, Study Director, Immunoassay, performing sample analysis.

Our multiplex Cannabinoid assay extracts Cannabidiol (CBD), Cannabinol (CBN), ∆9-tetrahydrocannabinol (THC) and its metabolites 11-hydroxy-∆9-THC (OH-THC) and 11-nor-9-carboxy-∆9-THC (COOH-THC) from only 100 μL of human plasma. The analytes are then separated by highly selective chromatography and the eluates analysed by tandem mass spectrometry (MS/MS). The method ranges are from 0.100 ng/mL to 10.0 ng/mL for CBD, CBN, THC and OH-THC and from 1.00 to 100 ng/mL for COOH-THC, with a run time of approximately 8 minutes per sample.

Highly sensitive and specific measurement of cannabinoids in human plasma improves the ability to characterize cannabinoid pharmacokinetics for medical cannabis drug development maximising therapeutic benefit and minimising negative side effects.

https://www.adelaidenow.com.au/business/sa-business-journal/south-australian-biotechlife-sciences-companies-to-shine-at-ausbiotech-2017-conference/news-story/2f2fc3b47100e94997ee75cef2913115

Article from the Advertiser, Oct 2017